Investigations into antimotion sickness drugs fall into two main categories: efficacy ('benefits') and side-effects ('costs'). This study was of the second type. Oral cinnarizine (30 mg: normal dose; and 75 mg: 2.5 x normal dose) and placebo, were investigated using a battery of automated mental, motor, physiological and other tests in twelve young healthy male volunteers. The higher cinnarizine dose level was chosen to exaggerate effects and make it easier to track them. Oral hyoscine (1.2 mg: 2 x normal dose) was employed as a positive internal control. Side-effects were almost exclusively due to hyoscine whereas cinnarizine was almost free of significant effects even at the higher dose of 75 mg. Hyoscine impaired performance 1-3 hours postdrug, whereas the effects of cinnarizine occurred approximately 5-7 hours postdrug. This paralleled the slower time-course for the protective action of cinnarizine against motion sickness noted in earlier studies. These results, taken in conjunction with previous trials, suggest that oral cinnarizine would seem less likely than hyoscine to produce unwanted decrements in performance.
Get full access to this article
View all access options for this article.
References
1.
Bittner A.C., Carter R.C., Kennedy R.S., Harbeson M.M., Krause M.1986Performance Evaluation Tests for Environmental Research (PETER): evaluation of 114 measuresPerceptual and Motor Skills63: 683-708
2.
Brand J.J. and Perry W L M1966Drugs used in motion sicknessPharmacological Reviews18: 895-924
3.
Broks P., Preston G.C., Traub M., Poppleton P., Ward C., Stahl, S.M.1988Modelling dementia: effects of scopolamine on memory and attentionNeuropsychologia26: 685-700
4.
Chandrasekaran S.K., Bayne W., Shaw J.E.1978Pharmacokinetics of drug permeation through the skinJournal of Pharmaceutical Sciences67: 1370-1374
5.
Declaration of Helsinki (1975) 'Adopted by the 18th World Medical Assembly, Helsinki, Finland (1964) and As Revised by the 29th World Medical Assembly, Tokyo, Japan (1975)'. In: Proposed International Guidelines for Biomedical Research Involving Human Subjects, pp. 35-40, WHO/CIOMS, Geneva (1982)
6.
Dhenim G., Whiteside T C D, Price T J G,Taylor J.G., Ernsting J.1978Aviation medicine. Health and clinical aspectsTri-Med Books Ltd, London
7.
Englund C.E., Reeves D.L., Shingledecker C.A., Thorne D.R., Wilson K.P., Hegge, F.W.1986Unified Tri-service Cognitive Performance Assessment Battery (UTC-PAB) (Rep. No. 86-1)US Army Research and Development Command, Fort Detrick, Maryland
8.
Godfraind T., Towse G., Van Neuten J.M.1982Cinnarizine- a selective calcium entry blockerDrugs of Today18: 27-42
9.
Ghoneim M., Mewaldt S.1975Effects of diazepam and scopolamine on storage, retrieval, and organisational processes in memoryPsychopharmacologia44: 257-262
10.
Herxheimer A.1958A comparison of atropine like drugs in manBritish Journal of Pharmacology13: 184-192
11.
Hundt H K L, Brown L.W., Clark E.C.1980Determination of cinnarizine in plasma by high-performance liquid chromatographyJournal of Chromatography Biomedical Applications, 183: 378-382
12.
Jennings J.R., Tahmoush A.J., Redmond D.P.1980Non-invasive measurement of peripheral vascular activity In: Techniques in psychophysiology. (Eds Martin I, Venables P H), pp 69-137, John Wiley & Sons, Chichester
13.
Kanto J., Klotz U.1988Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolateActa Anaethesiologica Scandinavica32: 69-78
14.
Kennedy R.S., Dunlap W.P., Jones M.B., Wilkes R.L., Bittner A.C.1985Automated portable test system (APTS): a performance envelope tool Society of Automative Engineers Technical Paper Series, No. 851775. Warrendale, Pennsylvania. ISSN 0148-7191
Morrison P.J., Bradbrook I.D., Rogers H.J.1979Plasma cinnarizine levels resulting from oral administration as capsule or tablet formulation investigated by gas-liquid chromatographyBritish Journal of Clinical Pharmacology7: 349-352
17.
Muir C., Metcalfe R.1983A comparison of plasma levels of hyoscine after oral and transdermal administrationJournal of Pharmaceutical and Biomedical Analysis1: 363-367
18.
Oosterveld W.J.1987The combined effect of cinnariziné and domperidone on vestibular susceptibilityAviation Space and Environmental Medicine58: 218-223
19.
Parrott A.C.1986a The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) on psychological performancePsychopharmacology89: 347-354
20.
Parrott A.C.1986b Transdermal scopolamine: effects of single and repeated patches upon aspects of visionHuman Psychopharmacology1: 109-115
21.
Parrott A.C., Golding J.F., Pethybridge R.J.1988The effects of single and repeated doses of oral hyoscine (scopolamine), cinnarizine, and placebo, upon psychological performance and physiological functioning INM Report 10/87, Institute of Naval Medicine, Gosport, England
22.
Parrott A.C., Wesnes K.1987Promethazine, scopolamine and cinnarizine: comparative time-course of psychological performance effectsPsychopharmacology92: 513-519
23.
Philipszoon A.J.1962Influence of cinnarizine on the labyrinth and on vertigoClinical Pharmacology and Therapeutics3: 181-190
24.
Pingree B J W, Hockenhull N., Wood M R F, Pethybridge R.J.1988A double blind placebo controlled comparison of early administered cinnarizine in increasing tolerance to a nauseogenic cross-coupled motion challenge. INM Report 24/87, Institute of Naval Medicine, Gosport, England
25.
Puttemans M., Bogaert M., Hoogewijs G., Dryon L., Massart D.L., Vanhaelst L.1984Determination of cinnarizine in whole blood and plasma by reversed phase HPLC and its application to a pharmacokinetic studyJournal of Liquid Chromatography7: 2237-2251
26.
Stott J R R, Hubble M.P., Spencer M.B.1984A double blind comparative trial of powdered ginger root, hyoscine hydrobromide, and cinnarizine in the prophylaxis of motion sickness induced by cross-coupled stimulation. AGARD Symposium Proceedings AGARD-cp-372, pp 39-1-39-6. Neuilly, France
27.
Strong R.1982Cinnarizine and performance. MS Trial No. 7. UnpublishedInstitute of Naval Medicine, Gosport, England
28.
Towse G.1980Cinnarizine - a labyrinthine sedativeJournal of Laryngology and Otology94: 1009-1015
29.
Wilkins A.J., Robson J.G.1987Cambridge low contrast gratings: instructions for useClement Clarke International Ltd, London
30.
Wood C.D., Manno J.E., Manno B.R., Redetzki H.M., Wood M.J., Mims M.E.1985Evaluation of antimotion sickness drug side-effects on performanceAviation Space and Environmental Medicine56: 310-316
